Roth MKM Reinstates Buy on LeMaitre Vascular, Announces $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jason Wittes reinstates a Buy rating on LeMaitre Vascular (NASDAQ:LMAT) and sets a price target of $100.
May 31, 2024 | 10:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM analyst Jason Wittes has reinstated a Buy rating on LeMaitre Vascular (NASDAQ:LMAT) and set a price target of $100.
The reinstatement of a Buy rating and a $100 price target by Roth MKM is likely to positively impact LeMaitre Vascular's stock price in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100